|
Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas
ZHENG Jia-wei,WANG Xu-kai, JIANG Cheng-hong, QIN Zhong-ping, FAN Xin-dong, LI Ka, YANG Yao-w, HUO Ran, LIU Shao-hua,ZHAO Ji-hong, WANG Xiao-yong, ZHOU De-kai, LEI Shao-rong
2016, 25 (6):
744-747.
[Summary] Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response. To reduce the side effects caused by systemic administration of propranolol, timolol maleate treatment has been increasingly used as an alternative to systemic β-blockers and watchful waiting for many IH patients in recent years. However, the appropriate indications, drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects still remains controversial. To standardize the use of topical timolol in treating IH, avoid overtreatment or under-treatment, as well as minimize complications, a Chinese expert consensus on the use of topical timolol treatment of IH has been approved and written by a multidisciplinary experts group based on an up-to-date literature review and repeated discussion, which can be used to reduce inappropriate variations in clinical practice and to promote the delivery of high quality, evidence-based health care for IH patients.
References |
Related Articles |
Metrics
|